EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study

Study limitation reported by the research below: “TEAEs were paradoxically higher in the placebo arm (63.6%) than the EP262 arm (19.0%), which is unusual and may reflect small sample size artifact; the paper does not appear to discuss this discrepancy.”